Therefore, at the present time, tau PET is most relevant for Alzheimer’s disease as a potential diagnostic biomarker but may be useful for tracking changes in pathology for both Alzheimer’s disease and other tauopathies. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.